transparent gif

 

Ej inloggad.

Göteborgs universitets publikationer

Does the target dose of neurohormonal blockade matter for outcome in Systolic heart failure in octogenarians?

Författare och institution:
Salim B. Barywani (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); Constantinos Ergatoudes (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); Maria Schaufelberger (Institutionen för medicin, avdelningen för molekylär och klinisk medicin); Max Petzold (Akademistatistik); Michael Fu (Institutionen för medicin, avdelningen för molekylär och klinisk medicin)
Publicerad i:
International Journal of Cardiology, 187 s. 666-672
ISSN:
0167-5273
Publikationstyp:
Artikel, refereegranskad vetenskaplig
Publiceringsår:
2015
Språk:
engelska
Fulltextlänk:
Sammanfattning (abstract):
Background: In elderly patients with chronic heart failure (CHF), a gap exists between widespread use of lower doses of angiotensin-converting enzyme inhibitors (ACEIs)/angiotensin-receptor blockers (ARBs) and beta-blockers (BBs) and guideline recommendations. Therefore, the aim of the present study was to investigate whether patients receiving >= 50% target dose outperform those receiving <50% target dose, despite maximum up-titration, and whether the target dose outperforms all other doses. Methods and Results: Patients (n=185) aged >= 80 years with CHF and left ventricular ejection fraction >= 40% referred (between January 2000 and January 2008) to two CHF outpatient clinics at two university hospitals, were included and retrospectively studied. Of the study population, 53% received the target dose of ACEIs/ARBs, whereas 26% received <50% of the target dose. Half received <50% of the target dose of BBs and 21% received the target dose. After >= 5 years of follow-up, all-cause mortality was 76.8%. Patients who received the target dose of ACEIs/ARBs had higher survival rates from all-cause mortality than those receiving <50% of target dose (HR = 0.6, 95% CI 0.4-0.9, P = 0.033), but those receiving >= 50% of target dose did not statistically differ from those who achieved target dose. This dose-survival relationship was not the case for BBs. Conclusions: Target dose of ACEIs/ARBs is associated with reduced all-cause five-year mortality in very old patients with systolic heart failure, despite that this was achievable in only about half of the patients. However, the clinical outcome of BB therapy is independent of BB dose when the target heart rate is achieved. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
Ämne (baseras på Högskoleverkets indelning av forskningsämnen):
MEDICIN OCH HÄLSOVETENSKAP ->
Klinisk medicin ->
Kardiologi ->
Kardiovaskulär medicin
Nyckelord:
Target dose, Systolic heart failure, Octogenarians, Mortality, Beta-blockers, ACEIs/ARBs, EUROPEAN-SOCIETY, RANDOMIZED-TRIAL, BETA-BLOCKERS, TASK-FORCE, GUIDELINES, HF, ASSOCIATION, DIAGNOSIS, INTERVENTION, CARVEDILOL, Cardiac & Cardiovascular Systems
Postens nummer:
218698
Posten skapad:
2015-06-23 10:58
Posten ändrad:
2016-08-24 08:54

Visa i Endnote-format

Göteborgs universitet • Tel. 031-786 0000
© Göteborgs universitet 2007